June 16, 2020
TILT Biotherapeutics Secures Over EUR 6 million to Advance Cancer Immunotherapies Into Clinic
Tilt Biotherapeutics has secured an additional EUR 6.2m, including EUR 4.5m equity, to advance its proprietary, best-in-class cytokine armed oncolytic adenovirus, TILT-123, into Phase 1 clinical trials